- Zacks Small Cap Research•28 days ago
While several studies over the last number of years, including the widely cited Reddy et al and Wapner et al studies which have positively influenced reimbursement policy, have all indicated that chromosomal microarray analysis (CMA) is the preferred genetic testing modality versus karyotyping due to the former's proven greater accuracy, that it provides more substantive clinical information and is able to be used on fresh as well as preserved (i.e.
- Zacks Small Cap Research•3 months ago
While CombiPGS (IVF test) volume slipped from 202 in Q4 of last year to 167 (-17%) in the most recent quarter, total PGS revenue was an identical $222k in both of those periods. That’s because, similar to miscarriage testing, it also experienced a nice jump in average pricing – moving from an average of $1,145 in 2015 (including $1,099 in Q4) to $1,329 in Q1 of this year. And similar revenue on lower volume but higher pricing should benefit margins due to less processing costs. And despite the 17% sequential (i.e.
|Bid||0.10 x 100|
|52wk Range||0.67 - 1.01|
|Day's Range||0.67 - 1.01|
|Avg Vol (3m)||N/A|
As of 4:00 PM EDT. Market closed.